TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plasma insulin and c-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma GIP and GLP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical Global Impression Scale (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neurodevelopment functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global cognitive level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pittsburg insomnia rating scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from baseline in sickness behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in anxiety state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: event rate of composite event
Endpoint domain: Mortality/survival
Primary endpoint: Pulmonary Safety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 30-day MACE rates
Endpoint domain: Adverse events/effects
Primary endpoint: termination of therapy
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cumulative days of hospital admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Area under the concentration time curve of paracetamol, amoxicillin and talinolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Post operative vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Consumption of other inotropes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipose tissue expandability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of any RV GE
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PDAC recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Events/Serious Adverse Events (AEs/SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of Stroke/MI/Death
Endpoint domain: Mortality/survival
Primary endpoint: three point shooting (S3P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in skeletal muscle FAs profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in erythrocytes FAs profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of additional or alternative treatment for stress urinary incontinence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean atrial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SpO (oxygen saturation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in Amblyopic-Eye Visual Acuity at 10 Weeks From Randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency Orthopedic Trauma Admissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of vision adaptation to low light after blueberry juice ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of vision adaptation to low light after placebo ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Heavy Drinking Days Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Drinks Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain threshold in degrees tolerated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in symptoms of depression, anxiety and stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hallux dorsal movement range degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety and tolerability of NFC-1
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of NFC-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrence-free Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Overall post surgical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal Consistency (IC) assessed as Cronbach's Alpha Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance percentage of the activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Spleen fold change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of unpleasant foot odor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Basic Mobility change over time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Applied Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of Morning Stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Unscheduled healthcare visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Peak Vertical Ground Reaction Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Peak Internal Knee Extension Moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Peak Knee Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ApoA-I level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time-dependent ceramic defect rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with COVID-19-like symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with SARS-CoV-2 nasopharyngeal swab (NPS) test positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recovery Experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Salivary Immunoglobulin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suitability of RebiSmart
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Any Adverse Events (AE), Any Serious Adverse Event (SAE) and Drug-related AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Achieving a Reduction in Peak Esophageal Eosinophil Count to < 5 Cells Per High Power Field (HPF) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of α1- and α2-gliadin-reactive CD4+ T Cells in Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of α1-gliadin-reactive CD4+ T Cells in Duodenal Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achievement of physical activity and dietary intake targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjects With at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects With Solicited Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Subjects With Solicited Local Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Brain Natriuretic Peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quick - Disabilities of the Arm, Shoulder and Hand (QuickDASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Initiation of interaction with PrEP Smart
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response to PrEP Smart prompt
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Who Experienced at Least One Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time for urinary retention resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of subjects who demonstrate a response to pre-operative chemotherapy and zaltrap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Heart failure symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic performance of pCLE image interpretation criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Developed Anti-andecaliximab Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Drug plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inferior vena cava collapsibility index changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Pulmonary Artery Systolic Pressure (PASP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Pulmonary Vascular Resistance (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: formation and composition of mucus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: maximum K-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Velocity of the cardiac walls
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychosexual distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Tolerated Dose (MTD) of Decitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Tetrahydrouridine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Skin Crepiness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline in Skin Elasticity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline in Skin Firmness Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline in Skin Sagging Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline in Skin Roughness (Visual) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Task Confidence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Visual Analog Scale Pain Ratings (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anterior Knee Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of coronary arteries with blood flow defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reperfusion success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Intensity of Adverse Events With Highest CTCAE Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Difference From Baseline for Liver Enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference From Baseline for Bilirubin, Creatinine and Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference From Baseline for Haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference From Baseline for Haematology and Differentials Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Perceived Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Inflammatory Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Vessel density of the retinal vascular network
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Sleep-disordered Breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Frequency of Technical Errors Related to Home-based Overnight Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of continuous remote cardiac monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptance of continuous remote cardiac monitoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Precision of brain metabolites concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: health-related quality of life: physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: health-related quality of life: role functioning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: health-related quality of life: social functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Area Under the Curve (AUC) of RMR for the first 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of RMR for the last 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of Respiratory Quotient (RQ) for the first 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC of RQ for the last 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weeks Gestation at Birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: pain while walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: magnesium status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Colonoscopy competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fagerström Test of Nicotine Dependence (FTND)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cigarettes consumed within the last month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Overall Lifting and Tightening of Submental and Neck Tissue Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in loudness discomfort level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of Pain Intensity Difference over 8-hours post-dose (SPID8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Achieve Intraoperative Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With the Indicated Types of Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-Treatment Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With the Indicated Adverse Events Related to Investigational Product During the On-treatment Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With an Adverse Event During the Follow-up Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Change in tremor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CRC screening intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: controlled attenuation parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: liver stiffness measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Increase in cervical cancer screening participation
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Type II Diabetes Mellitus control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Negative outcomes related to false-negative diagnosis of choledocholithiasis
Endpoint domain: Adverse events/effects
Primary endpoint: Negative outcomes related to endoscopic procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of grade ≥3 thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Rapid Visual Information Processing task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Hayling Sentence Completion test
Endpoint domain: Cognitive functioning
Primary endpoint: Increased Cardiac Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Core clock gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Ratios of Log-transformed Transit Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Incontinence Quality of Life (I-QoL) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain scale (Numeric Rating Scale: 0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial meal-associated metabolic response patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of estraderm treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decrease of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Long term reversible contraceptives uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 10 meters walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual ankle instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-adjusted hypoglycaemic symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroop color-word test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Conners parent rating scale-revised short (CPRS-RS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of children diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximally Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best spectacle correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIN III lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: functional outcome on SF-36
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urodynamic assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in QT/QTc interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intracardiac triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation of volume of rectal constant sensation to need to defecate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: length of stay postoperative in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Dopamine synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dopamine D2 receptor availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on rating scale for perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erythrocyte membrane integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time Until Device Posts Sensor Off
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration vs time curve from zero to infinity for total drug (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum total drug concentration in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes